{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T04:30:50Z","timestamp":1781843450324,"version":"3.54.5"},"reference-count":31,"publisher":"Copernicus GmbH","issue":"2","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Bone Joint Infect."],"abstract":"<jats:p>Abstract. Background: Acinetobacter baumannii complex is an increasingly important cause of osteomyelitis. It is considered a difficult to treat agent, due to increasing antimicrobial resistance and few available therapeutic options.Objective: To compare effectiveness and tolerability of tigecycline and colistin in patients with osteomyelitis caused by carbapenem-resistant A. baumannii complex (CRABC).Methods: This retrospective review included all patients admitted to a 150-bed tertiary hospital from 2007 to 2015 with microbiologically confirmed CRABC osteomyelitis for which they received tigecycline or colistin. Data on demographic and clinical characteristics, adverse events, and outcomes 12 months after the end of antimicrobial treatment were analysed and stratified according to the antimicrobial used.Results: 65 patients were included, 34 treated with colistin and 31 with tigecycline. There were significantly more men (P = 0.028) in the colistin group, and more smokers (P = 0.021) and greater occurrence of chronic osteomyelitis (P = 0.036) in the tigecycline treatment group. Median duration of therapy was 42.5 days for colistin and 42 days for tigecycline, with no significant difference. Overall incidence of adverse events was higher in the colistin group (P = 0.047). In particular, incidence of renal impairment was also higher in this group (P = 0.003). Nausea and vomiting were more frequent with tigecycline (P = 0.046). There were no significant differences between groups in relapse, amputation, or death.Conclusions: Tigecycline had a better safety profile than colistin in the treatment of osteomyelitis due to CRABC, with no significant difference in outcomes after 12 months of follow-up.\n                    <\/jats:p>","DOI":"10.7150\/jbji.42448","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T12:03:16Z","timestamp":1582804996000},"page":"60-66","source":"Crossref","is-referenced-by-count":13,"title":["Tigecycline Versus Colistin in the Treatment of Carbapenem-resistant Acinetobacter baumannii Complex Osteomyelitis"],"prefix":"10.5194","volume":"5","author":[{"given":"Priscila R.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir C.","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo S.","family":"Saconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos C.","family":"Leonhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kodi E.","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge S.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Lucia","family":"L.M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3145","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Cerceo E, Deitelzweig SB, Sherman BM. et al. Multidrug-resistant Gram-negative bacterial infections in the hospital setting: overview, implications for clinical practice, and emerging treatment options. Microb Drug Resist. 2016;22:412\u201331. https:\/\/doi.org\/ 10.1089\/mdr.2015.0220.","DOI":"10.1089\/mdr.2015.0220"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bassetti M, Russo A, Carnelutti A. et al. Antimicrobial resistance and treatment: an unmet clinical safety need. Expert Opin Drug Saf. 2018;17:669\u201380. https:\/\/doi.org\/ 10.1080\/14740338.2018.1488962.","DOI":"10.1080\/14740338.2018.1488962"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Munoz-Price LS, Weinstein RA. Acinetobacter infection. N Engl J Med. 2008;358:1271\u201381. https:\/\/doi.org\/ 10.1056\/NEJMra070741.","DOI":"10.1056\/NEJMra070741"},{"key":"ref4","unstructured":"Lima AL, Oliveira PR, Paula AP. Acinetobacter infection. N Engl J Med. 2008;358:2846."},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Mody RM, Zapor M, Hartzell JD. et al. Infectious complications of damage control orthopedics in war trauma. J Trauma. 2009;67:758\u201361. https:\/\/doi.org\/ 10.1097\/TA.0b013e3181af6aa6.","DOI":"10.1097\/TA.0b013e3181af6aa6"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yun HC, Branstetter JG, Murray CK. Osteomyelitis in military personnel wounded in Iraq and Afghanistan. J Trauma. 2008;64(Suppl 2):S163\u20138. https:\/\/doi.org\/ 10.1097\/TA.0b013e318160868c.","DOI":"10.1097\/TA.0b013e318160868c"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Oliveira PR, Carvalho VC, da Silva Felix C. et al. The incidence and microbiological profile of surgical site infections following internal fixation of closed and open fractures. Rev Bras Ortop. 2016;51:396\u20139. https:\/\/doi.org\/ 10.1016\/j.rboe.2015.09.012. [PMC free article]","DOI":"10.1016\/j.rboe.2015.09.012"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Davis KA, Moran KA, McAllister CK. et al. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis. 2005;11:1218\u201324. [PMC free article]","DOI":"10.3201\/1108.050103"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Fily F, Ronat JB, Malou N. et al. Post-traumatic osteomyelitis in Middle East war-wounded civilians: resistance to first-line antibiotics in selected bacteria over the decade 2006-2016. BMC Infect Dis. 2019;19:103.. https:\/\/doi.org\/ 10.1186\/s12879-019-3741-9. [PMC free article]","DOI":"10.1186\/s12879-019-3741-9"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Weintrob AC, Murray CK, Xu J. et al. Early infections complicating the care of combat casualties from Iraq and Afghanistan. Surg Infect (Larchmt) 2018;19:286\u201397. https:\/\/doi.org\/ 10.1089\/sur.2017.240. [PMC free article]","DOI":"10.1089\/sur.2017.240"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Vanegas JM, Higuita LF, Vargas CA. et al. Carbapenem-resistant Acinetobacter baumannii causing osteomyelitis and infections of skin and soft tissues in hospitals of Medell\u00edn, Colombia. Biomedica. 2015;35:522\u201330. https:\/\/doi.org\/ 10.7705\/biomedica.v35i4.2572.","DOI":"10.7705\/biomedica.v35i4.2572"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Landersdorfer CB, Bulitta JB, Kinzig M. et al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet. 2009;48:89\u2013124. https:\/\/doi.org\/ 10.2165\/0003088-200948020-00002.","DOI":"10.2165\/00003088-200948020-00002"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006;26:1099\u2013110.","DOI":"10.1592\/phco.26.8.1099"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tsachouridou O, Georgiou A, Nanoudis S. et al. Prolonged and high dosage of tigecycline - successful treatment of spondylodiscitis caused by multidrug-resistant Acinetobacter baumannii: a case report. J Med Case Rep. 2017;11:186.. https:\/\/doi.org\/ 10.1186\/s13256-017-1357-5. [PMC free article]","DOI":"10.1186\/s13256-017-1357-5"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Schafer JJ, Mangino JE. Multidrug-resistant Acinetobacter baumannii osteomyelitis from Iraq. Emerg Infect Dis. 2008;14:512\u20134. https:\/\/doi.org\/ 10.3201\/eid1403.070128. [PMC free article]","DOI":"10.3201\/eid1403.070128"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Negi S, Koreeda D, Kobayashi S. et al. Acute kidney injury: epidemiology, outcomes, complications, and therapeutic strategies. Semin Dia. 2018;31:519\u201327. https:\/\/doi.org\/ 10.1111\/sdi.12705.","DOI":"10.1111\/sdi.12705"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Rao N, Ziran BH, Lipsky BA. Treating osteomyelitis: antibiotics and surgery. Plast Reconstr Surg. 2011;127(Suppl 1):177\u201387. https:\/\/doi.org\/ 10.1097\/PRS.0b013e3182001f0.","DOI":"10.1097\/PRS.0b013e3182001f0f"},{"key":"ref18","unstructured":"Nicolau DP, Quintana A, Korth-Bradley JM. et al. A rationale for maintaining current tigecycline breakpoints as established by the USA Food and Drug Administration. Arch Clin Microbiol. 2015;6:1\u201312. [Google Scholar]"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Jones RN, Ferraro MJ, Reller LB. et al. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007;45:227\u201330. [PMC free article]","DOI":"10.1128\/JCM.01588-06"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Siebenb\u00fcrger G, Grabein B, Schenck T, Kammerlander C, B\u00f6cker W, Zeckey C. Eradication of Acinetobacter baumannii\/Enterobacter cloacae complex in an open proximal tibial fracture and closed drop foot correction with a multidisciplinary approach using the Taylor Spatial Frame: a case report. Eur J Med Res. 2019;24:2. [PMC free article]","DOI":"10.1186\/s40001-019-0360-2"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Kuo SC, Wang FD, Fung CP. et al. Clinical experience with tigecycline as treatment for serious infections in elderly and critically ill patients. J Microbiol Immunol Infect. 2011;44:45\u201351. https:\/\/doi.org\/ 10.1016\/j.jmii.2011.01.009.","DOI":"10.1016\/j.jmii.2011.01.009"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Lima AL, Oliveira PR, Carvalho VC. et al. Recommendations for the treatment of osteomyelitis. Braz J Infect Dis. 2014;18:526\u201334. https:\/\/doi.org\/ 10.1016\/j.bjid.2013.12.005.","DOI":"10.1016\/j.bjid.2013.12.005"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Vardakas KZ, Falagas ME. Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2017;49:233\u20138. https:\/\/doi.org\/ 10.1016\/j.ijantimicag.2016.07.023.","DOI":"10.1016\/j.ijantimicag.2016.07.023"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Griffin AT, Harting JA, Christensen DM. Tigecycline in the management of osteomyelitis: a case series from the bone and joint infection (BAJIO) database. Diagn Microbiol Infect Dis. 2013;77:273\u20137. https:\/\/doi.org\/ 10.1016\/j.diagmicrobio.2013.07.014.","DOI":"10.1016\/j.diagmicrobio.2013.07.014"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ni W, Han Y, Zhao J. et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;47:107\u201316. https:\/\/doi.org\/ 10.1016\/j.ijantimicag.2015.11.011.","DOI":"10.1016\/j.ijantimicag.2015.11.011"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hogan A, Heppert VG, Suda AJ. Osteomyelitis. Arch Orthop Trauma Surg. 2013;133:1183\u201396. https:\/\/doi.org\/ 10.1007\/s00402-013-1785-7.","DOI":"10.1007\/s00402-013-1785-7"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Maffulli N, Papalia R, Zampogna B. et al. The management of osteomyelitis in the adult. Surgeon. 2016;14:345\u201360. https:\/\/doi.org\/ 10.1016\/j.surge.2015.12.005.","DOI":"10.1016\/j.surge.2015.12.005"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Carvalho VC, Oliveira PR, Dal-Paz K. et al. Gram-negative osteomyelitis: clinical and microbiological profile. Braz J Infect Dis. 2012;16(Suppl 1):63\u20137.","DOI":"10.1590\/S1413-86702012000100011"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"de Sanctis J, Teixeira L, van Duin D. et al. Complex prosthetic joint infections due to carbapenemase-producing Klebsiella pneumoniae: a unique challenge in the era of untreatable infections. Int J Infect Dis. 2014 Aug;25:73\u201378. https:\/\/doi.org\/ 10.1016\/j.ijid.2014.01.028. [PMC free article]","DOI":"10.1016\/j.ijid.2014.01.028"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018;16:91\u2013102. https:\/\/doi.org\/ 10.1038\/nrmicro.2017.148. [PMC free article]","DOI":"10.1038\/nrmicro.2017.148"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Vourli S, Dafopoulou K, Vrioni G. et al. Evaluation of two automated systems for colistin susceptibility testing of carbapenem-resistant Acinetobacter baumannii clinical isolates. J Antimicrob Chemother. 2017;72:2528\u201330. https:\/\/doi.org\/ 10.1093\/jac\/dkx186.","DOI":"10.1093\/jac\/dkx186"}],"container-title":["Journal of Bone and Joint Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jbji.copernicus.org\/articles\/5\/60\/2020\/jbji-5-60-2020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T09:07:19Z","timestamp":1596532039000},"score":1,"resource":{"primary":{"URL":"https:\/\/jbji.copernicus.org\/articles\/5\/60\/2020\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.7150\/jbji.42448","relation":{},"ISSN":["2206-3552"],"issn-type":[{"value":"2206-3552","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}